Does Efavirenz Interact with Caspofungin Acetate?
CDI records a moderate classification for Efavirenz and Caspofungin Acetate. The stored summary is: Efavirenz is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered. The mechanism involves hepatic cyp enzyme induction reduces caspofungin acetate plasma concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Efavirenz Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Hepatic CYP enzyme induction reduces caspofungin acetate plasma concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Efavirenz and your doctor is considering prescribing Caspofungin Acetate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider